Evolent Health (EVH) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

External links

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Ecosystem Environment Environmental Green Leach Life Cycle Materials Nature Ocean Offset Package Pandemic Waste Wind Access African American Asian Attrition Benefits Black Charity Collective Bargaining Community Community Engagement Culture Customer Customer Satisfaction Cyber Cyber Security Cybersecurity Data Privacy Data Security Death Demographic Demographics Disability Diversity Diversity and Inclusion Employee Employee Engagement Employee Mobility Employee Training Engagement Ethnic Ethnicity Gender Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Human Rights Incident Injury LGBTQ Minority Parental Leave Pay Equity Pay for Performance Perquisites Privacy Recruit Recruitment Reimbursement Resource Group Retention Retirement Safety Satisfaction Sexual Harassment Skilled Skills Social Stakeholder Supplier Supply Chain Talent Training Union Women Workers Workforce Action Plan Antitrust Assessment Assurance Attorneys General Audit Board Refreshment Bonus Bribe Class Action Lawsuit Classified Classified Board Clawback Commitment Conflict of Interest Corporate Governance Corporate Purpose Corruption Department of Enterprise Risk Management ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Independent Chair Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Mission Oversee Oversight Perquisite Plaintiff Pledging Poison Pill Proxy Access Purpose R&D Recoup Reputation Reputational Reputational Risk Research and Development Resilient Responsibility Responsible Self-evaluation Single Trigger Special Meeting Stockholder Engagement Stockholder Outreach Strategy Supermajority Sustainability Sustainable Targets Tax Tax Gross Up Tenure Transparency Transparent Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

(a) Evolent Health, Inc. held its 2022 annual meeting of stockholders on June 9, 2022. At the 2022 annual meeting, the Company’s stockholders voted on three proposals. The proposals are described in the Company’s definitive proxy statement on Schedule 14A for the 2022 annual meeting filed with the Securities and Exchange Commission on April 29, 2022.

(b) The final voting results with respect to each proposal voted upon at the 2022 annual meeting are set forth below.

Proposal 1

The Company’s stockholders elected each of the seven Class I and Class III director nominees named in the proxy statement to the Board of Directors for a one-year term expiring at the Company’s 2023 annual meeting of stockholders and until their respective successors are duly elected and qualified, as set forth below:

	For	Against	Abstentions	Broker Non-Votes

Seth Blackley	76,878,128	3,449,467	44,211	3,284,716
David Farner	73,039,346	6,660,219	672,241	3,284,716
Peter Grua	79,643,956	683,639	44,211	3,284,716
Craig Barbarosh	75,885,686	3,814,685	671,435	3,284,716
Kim Keck	75,734,162	3,966,209	671,435	3,284,716
Cheryl Scott	76,459,032	3,868,563	44,211	3,284,716
Frank Williams	75,386,739	4,940,856	44,211	3,284,716

Proposal 2

The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2022, as set forth below:


For	Against	Abstentions
83,603,510	30,952	22,060

Proposal 3

The Company’s stockholders approved the compensation of our named executive officers for 2021 on an advisory basis, as set forth below:

For						Against						Abstentions						Broker Non-Votes

77,483,402						2,838,763						49,641						3,284,716